
    
      This is a multicenter, randomized, double-blind, double-dummy, parallel-group study. Subjects
      who meet all the inclusion/exclusion criteria will be randomly assigned to 1 of 2 treatment
      groups, Rabeprazole ER 50 mg or Esomeprazole 40 mg for the treatment of moderate to severe
      erosive GERD.
    
  